By Marie Daghlian
Cephalon (CEPH) is acquiring biotech startup Gemin X Pharmaceuticals for as much as $525 million to access its pipeline of first-in-class cancer therapeutics. It will pay $225 million in cash upfront, and up to $300 million more upon the achievement of certain regulatory and sales milestones.
Gemin X?s drug pipeline is based on reactivating programmed forms of cell death through the inhibition of metabolism in tumor cells. Its lead therapeutic candidate, obatoclax, is currently completing a mid-stage trial evaluating its safety and efficacy as a first line treatment in combination with standard therapy in patients with extensive stage small cell lung cancer?a disease with no currently approved treatment other than chemotherapy. Data from the trial will be presented at an upcoming meeting.
Cephalon has been on a deal-making spree in the past twelve months in an effort to boost revenues ahead of its blockbuster wakefulness drug Provigil
Complete Story »
ROCKWELL AUTOMATION RF MICRO DEVICES RED HAT RADISYS RACKABLE SYSTEMS
No comments:
Post a Comment